Biogena Group Invest AG

As of January 31, 2026, Biogena Group Invest AG carries a market capitalization of 12.13M, placing it among publicly traded companies globally. Its enterprise value stands at 12.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of January 31, 2026, Biogena Group Invest AG has 3.99M shares outstanding.

As of January 31, 2026, Biogena Group Invest AG trades at a trailing price-to-earnings ratio of 41.35. The price-to-sales ratio is 34.55, and the price-to-book ratio stands at 1.38.

As of January 31, 2026, Biogena Group Invest AG trades at an EV/EBITDA multiple of 67.62 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 34.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 67.62 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 12.11M versus a market cap of 12.13M, with the gap driven by net debt and cash on the balance sheet.

As of January 31, 2026, Biogena Group Invest AG maintains a current ratio of 26.35, meaning it holds 26.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended January 31, 2026, Biogena Group Invest AG posted a return on equity (ROE) of 3.35, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.01 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.30, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.35, useful for judging operating efficiency across full business cycles.

Over the twelve months ended January 31, 2026, Biogena Group Invest AG recorded 3,528.98 in income tax expense. That works out to an effective tax rate of 1.19, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 296,855.02, leaving 293,326.04 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Biogena Group Invest AG's stock has gained approximately 72.30% over the past 52 weeks. The 50-day moving average sits at 5.19, while the 200-day moving average is 3.96.

Over the twelve months ended January 31, 2026, Biogena Group Invest AG generated 351,057.60 in revenue and converted that into 293,326.04 in net income, yielding earnings per share of 0.07. EBITDA reached 179,027.87, while operating income came in at 179,027.87.

These figures are as of January 31, 2026. Total book value stands at 8.80M, with working capital of 1.29M providing operational flexibility.

These figures cover the twelve months ended January 31, 2026. The operating margin of 51.00 and net profit margin of 83.55 provide insight into operational efficiency.

Biogena Group Invest AG's most recent stock split took place on April 8, 2021 with a 647:714 split ratio.

As of January 31, 2026, Biogena Group Invest AG has an Altman Z-Score of 116.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.